Binding Site, the UK clinical diagnostic company, has announced that it will be collaborating with the US-based International Myeloma Foundation (IMF) on its Black Swan Research Initiative. Binding Site’s Freelite® and Hevylite® tests, two unique blood tests for measuring serum free light chains and intact monoclonal heavy chains respectively, will form part of the toolkit to help achieve ‘a path towards curing myeloma’.

Read the full article